These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31969338)

  • 1. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
    Burke MJ; Kostadinov R; Sposto R; Gore L; Kelley SM; Rabik C; Trepel JB; Lee MJ; Yuno A; Lee S; Bhojwani D; Jeha S; Chang BH; Sulis ML; Hermiston ML; Gaynon P; Huynh V; Verma A; Gardner R; Heym KM; Dennis RM; Ziegler DS; Laetsch TW; Oesterheld JE; Dubois SG; Pollard JA; Glade-Bender J; Cooper TM; Kaplan JA; Farooqi MS; Yoo B; Guest E; Wayne AS; Brown PA
    Clin Cancer Res; 2020 May; 26(10):2297-2307. PubMed ID: 31969338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    August KJ; Guest EM; Lewing K; Hays JA; Gamis AS
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28062. PubMed ID: 31724803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
    Burke MJ; Lamba JK; Pounds S; Cao X; Ghodke-Puranik Y; Lindgren BR; Weigel BJ; Verneris MR; Miller JS
    Am J Hematol; 2014 Sep; 89(9):889-95. PubMed ID: 24891274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
    Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
    Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.
    Place AE; Pikman Y; Stevenson KE; Harris MH; Pauly M; Sulis ML; Hijiya N; Gore L; Cooper TM; Loh ML; Roti G; Neuberg DS; Hunt SK; Orloff-Parry S; Stegmaier K; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27062. PubMed ID: 29603593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Messinger YH; Gaynon PS; Sposto R; van der Giessen J; Eckroth E; Malvar J; Bostrom BC;
    Blood; 2012 Jul; 120(2):285-90. PubMed ID: 22653976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
    Messinger Y; Gaynon P; Raetz E; Hutchinson R; Dubois S; Glade-Bender J; Sposto R; van der Giessen J; Eckroth E; Bostrom BC
    Pediatr Blood Cancer; 2010 Aug; 55(2):254-9. PubMed ID: 20582937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
    Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
    Pommert L; Schafer ES; Malvar J; Gossai N; Florendo E; Pulakanti K; Heimbruch K; Stelloh C; Chi YY; Sposto R; Rao S; Huynh VT; Brown P; Chang BH; Colace SI; Hermiston ML; Heym K; Hutchinson RJ; Kaplan JA; Mody R; O'Brien TA; Place AE; Shaw PH; Ziegler DS; Wayne A; Bhojwani D; Burke MJ
    Am J Hematol; 2022 May; 97(5):613-622. PubMed ID: 35180323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
    Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
    Kadia TM; Kantarjian HM; Thomas DA; O'Brien S; Estrov Z; Ravandi F; Jabbour E; Pemmaraju N; Daver N; Wang X; Jain P; Pierce S; Brandt M; Garcia-Manero G; Cortes J; Borthakur G
    Am J Hematol; 2015 Feb; 90(2):120-4. PubMed ID: 25368968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
    Parker C; Waters R; Leighton C; Hancock J; Sutton R; Moorman AV; Ancliff P; Morgan M; Masurekar A; Goulden N; Green N; Révész T; Darbyshire P; Love S; Saha V
    Lancet; 2010 Dec; 376(9757):2009-17. PubMed ID: 21131038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
    Faderl S; Thomas DA; O'Brien S; Ravandi F; Garcia-Manero G; Borthakur G; Ferrajoli A; Verstovsek S; Ayoubi M; Rytting M; Feliu J; Kantarjian HM
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):54-9. PubMed ID: 21454191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.
    Nickel RS; Keller F; Bergsagel J; Cooper T; Daves M; Sabnis H; Lew G
    Pediatr Blood Cancer; 2014 May; 61(5):810-4. PubMed ID: 24357218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.
    Hunault-Berger M; Leguay T; Thomas X; Legrand O; Huguet F; Bonmati C; Escoffre-Barbe M; Legros L; Turlure P; Chevallier P; Larosa F; Garban F; Reman O; Rousselot P; Dhédin N; Delannoy A; Lafage-Pochitaloff M; Béné MC; Ifrah N; Dombret H;
    Haematologica; 2011 Feb; 96(2):245-52. PubMed ID: 20971822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.